# A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanc

Source: https://onco.cc/trials/nct07821684/  
OnCo record `nct07821684` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of telisotuzumab adizutecan, docetaxel and ramucirumab in lung cancer, run by AbbVie, not yet recruiting.

## Summary

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07821684 by AbbVie, with a registry enrolment figure of 660 participants, started 2027-01-06 and due to reach its primary completion in 2031-04. Interventions recorded: Telisotuzumab Adizutecan; Docetaxel; Ramucirumab. Conditions listed: Non-Squamous Non-Small Cell Lung Cancer. Primary outcome: Objective Response (OR) Based on Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1; Overall Survival (OS). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed metastatic/locally advanced non-squamous NSCLC". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07821684
- Phase: 3
- Setting: A Phase 3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Expressing c-Met Protein Level Above a Defined Cutoff
- Sponsor: AbbVie
- Enrolled: 660

## Sources

- ClinicalTrials.gov NCT07821684: https://clinicaltrials.gov/study/NCT07821684

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/), [Telisotuzumab adizutecan](https://onco.cc/drugs/telisotuzumab-adizutecan/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07821684.json